NCT05083182: An ongoing trial by Janssen Research & Development, LLC
This trial is ongoing. It must report results 1 year, 11 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT05083182 |
|---|---|
| Title | A Phase 3 Multicenter, Open-label Study to Evaluate the Efficacy, Pharmacokinetics, Safety, and Immunogenicity of Subcutaneously Administered Ustekinumab or Guselkumab in Pediatric Participants With Active Juvenile Psoriatic Arthritis (PSUMMIT-Jr) |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Aug. 30, 2022 |
| Completion date | Dec. 10, 2026 |
| Required reporting date | Dec. 10, 2027, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |